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Hyaluronan is a matrix polymer prominent in tissues undergoing rapid growth, development, and repair, in embryology and
during malignant progression. It reaches 107 Daltons in size but also exists in fragmented forms with size-speciﬁc actions. It
has intracellular forms whose functions are less well known. Hyaluronan occurs in all vertebrate tissues with 50% present in
skin. Hyaluronan provides a scaﬀold on which sulfated proteoglycans and matrix proteins are organized. These supramolecular
structures are able to entrap water and ions to provide tissues with hydration and turgor. Hyaluronan is recognized by membrane
receptors that trigger intracellular signaling pathways regulating proliferation, migration, and diﬀerentiation. Cell responses are
often dependent on polymer size. Catabolic turnover occurs by hyaluronidases and by free radicals, though proportions between
these have not been determined. New aspects of hyaluronan biology have recently become realized: involvement in autophagy, in
the pathology of diabetes., the ability to modulate immune responses through eﬀects on T regulatory cells and, in its fragmented
forms, by being able to engage several toll-like receptors. It is also apparent that hyaluronan synthases and hyaluronidases are
regulated at many more levels than previously realized, and that the several hyaluronidases have functions in addition to their
enzymatic activities.
1.Introduction
Hyaluronan (HA, hyaluronic acid) is a glycosaminoglycan
(GAG) polymer that is a major component of the extracel-
lular matrix (ECM) [1, 2]. It can occur as a high-molecular-
weight (HMW) polymer, reaching >107 Da, but also exists in
muchsmallerforms.ThemyriadofshorterHAchainsoccurs
w i t ha c t i v i t i e st h a ta p p e a rt ob es i z es p e c i ﬁ c .H Ai sm a j o r
component of the ECM, particularly prominent during
embryogenesis, in tissues undergoing rapid growth and
development, during repair and regeneration, and in as-
sociationwithaggressivemalignancies.Recentevidenceindi-
cates that HA also exists in an intracellular form. However,
its functions therein are not as well established. Here, we
attempt to summarize recent ﬁndings of this widely dis-
tributed GAG and to correlate speciﬁc functions with size
and location of this intriguing carbohydrate chain.
2. Hyaluronan,a HighlyIronicAcid
2.1. Overview. HA is a strictly alternating disaccharide of N-
acetylglucosamine and glucuronic acid connected by β1-4
and β1-3 glycosidic bonds, respectively. It is the only GAG
that is not sulfated and without a covalent attachment to a
proteoglycan core protein. It participates in many disparate
processes, such as cell motility, tissue proliferation, embry-
onic development, malignant progression and metastasis,
wound healing, and angiogenesis. HA is extruded into the
extracellular space through the plasma membrane as it is
being synthesized. Otherwise, the cell would become en-
gorged with this huge space-occupying polymer.
HA has a relatively small volume of solvent water, but
because of its great negative charge at neutral pH, it has
an immense volume of aqueous domain that accompanies
the molecule. This forces open tissue spaces through which
cells can travel. The HA molecule, by binding to cell2 Biochemistry Research International
surface receptors that interact with the cytoskeleton and that
stimulate signal transduction pathways, endow cells with
motility [3].
2.2. Hyaluronan of the Extracellular Matrix. Hyaluronan, in
addition to occurring in a great number of sizes, also exists
in a number of diﬀerent forms in the vertebrate ECM. It
can be ﬁrmly intercalated within a proteoglycan complex
such as in cartilage, where it is held by electrostatic in-
teractions by aggrecan and link protein with an avidity
that approaches that of the avidin: biotin complex. HA
can loosely be associated with an array of proteoglycans
in loose connective tissues and in tissues undergoing rapid
proliferation, development repair, and regeneration. It has a
key role in organization of the entire ECM. HA can occur
bound to the surface of cells by a number of membrane
receptors.
The argument can be made that there are actually two
forms of ECM, a widespread general intercellular matrix,
and a more delicate pericellular matrix, often referred to as
a glycocalyx. HA is a major component of both of these
matrices, but is the greater portion of the total matrix of the
glycocalyx. The glycocalyx of endothelial cells extends into
the vascular lumen. The HA of the endothelial glycocalyx
controls permeability and the diﬀusion of small solutes
[4–6]. The functional lumen of the vascular system is far
smaller than reﬂected in formalin-ﬁxed tissue sections,
occupying less that 25% of the apparent volume. There
are proteoglycan- and HA-rich fronds that extend into the
lumen, referred to by physiologists as “Duling’s Lawn.” This
“lawn” disappears in a murine model, albeit transiently,
following an in vivo injection of hyaluronidase (B.R. Duling,
personal communication).
One of the several nonenzymatic functions of the cell-
surface-bound hyaluronidase, Hyal2, is formation of the
glycocalyx [7]. In structures such as bone, tendon, cartilage,
and loose connective tissues, the ECM constitutes a major
proportion of total tissue mass. In the intimate pericellular
matrix that envelops individual cells, HA remains consis-
tently the major ECM component and is critically involved
inmechanotransduction,inroundingofcellsduringmitosis,
in adhesion and deadhesion of cells, and in cell locomotion
[8].
How HA becomes distributed into the two ECM compo-
nentsfollowingsynthesisisprobablymanagedbythebinding
proteins that interact and decorate the polymer, including
cell-bound receptors, and proteins with a wide range of
avidity for HA. Such binding occurs in response to speciﬁc
tissue needs and stresses, particularly in inﬂammation.
The polymer also exists in a freely circuiting form
in lymphatics and in the cardiovascular system where it
can be decorated by a number of binding proteins termed
the hyaladherens, attached by both electrostatic and cova-
lent interactions. These include cross-linking proteins such
as tenascin, TSG-6 (tumor-necrosis-factor-stimulated gene
6), inter-alpha-trypsin inhibitor, pentraxin, and throm-
bospondin. Even in these circulating forms, there is probably
some structural organization conferred by these associated
proteins [9, 10].
A universal transitional ECM has recently become iden-
tiﬁed that enwraps muscle bundles, consisting of HA, ten-
ascin, and ﬁbronectin. This complex, synthesized by the
deep fascia, supports limb regeneration in the salamander
[11]. In higher vertebrates, this same complex may support
muscle regeneration and repair. In surgery, it is customary in
procedures involving limbs, muscles, and nerves, to provide
a “fascial ﬂap.” This improves recovery, but no mechanism
has ever been formulated as to how this occurs. The fascial
“transitional matrix,” rich in HA, may provide such a
mechanism.
2.3. Hyaluronan Cables. Hyaluronan can also exist in cable
forms, as has recently been documented [12], reﬂecting the
remarkable diversity of this simple molecule. Incorporation
of the heavy chain of IαI (inter-alpha-trypsin inhibitor) into
bundlesofHAfacilitatesformationofthesecables,becoming
simultaneously adhesion depots for inﬂammatory cells.
These HA cables may be able to modulate the intensity of
the inﬂammatory response. In marked contrast, the HA of
the pericellular glycocalyx is not able to bind inﬂammatory
cells, and actively excludes them. Of interest is that IαIi sn o t
associated with the HA of the glycocalyx and may therefore
be the key mechanism. Other HA-binding proteins, such as
versican, are found in both cables and in the glycocalyx.
2.4. Intracellular Hyaluronan. Intracellular HA has been well
documented since 1999 [13–15], but its precise functions
remain elusive. Many obstacles hinder precise localization,
the most important being masking of HA by HA-binding
macromolecules termed hyaladherens. These include pro-
teoglycans, glycoproteins, and HA receptors. Despite that
problem, many studies indicate that HA is indeed present
intracellularly. Such HA is more prominent in proliferating
cells where it is associated with microtubules, RHAMM
(receptor for HA-mediated motility), and the mitotic spin-
dle, suggesting functions associated with some aspects of
mitosis and motility [14]. Intracellular HA is also more
prominent in association with the stem cell niche, and with
cellular stress responses such as inﬂammation. However,
precise molecular mechanisms of such HA actions remain
elusive.
Other conundrums associated with the distinction be-
tween intracellular and extracellular HA are the mode of
synthesis, and distribution. Is all HA that is synthesized,
secreted by cells through the plasma membrane and intra-
cellularHA is then taken up by cells secondarily? Or are there
twopathwaysofHAsynthesis,oneforexportandanotherfor
maintenance within the intracellular compartment. Intracel-
lular HA is found intracellularly in the cytoplasm, nucleus,
and nucleolus. What are the mechanisms for the distribution
to HA to each speciﬁc location?
3.The HyaluronanSynthases
Three isoforms of a single enzyme synthesize HA, dual-
headedtransferasesthatutilizeassubstratesalternatelyUDP-
glucuronic acid, and UDP-N-acetylglucosamine. These areBiochemistry Research International 3
membrane proteins, located within and on the inner surface
of the plasma membrane. The HA synthases are themselves
synthesized in the endoplasmic reticulum in an inactive
form,transported throughthe Golgiinaninactive form,and
are then inserted into the plasma membrane. The enzymes
must be activated, and they then begin to add alternatively
the glucuronic acid and N-acetylglucosamine units to the
reducing end of the growing polymer from their respective
UDP precursors.
The active sites of the HA synthase enzymes protrude
from the inner surface of the cell membrane. The newly
made HA is extruded through the plasma membrane into
the extracellular space, either into the ECM or on to the cell
surface as it is being synthesized, permitting unconstrained
polymer growth without destruction of the cell.
Thethreesynthasegenesinthemammaliangenomecode
for HAS1, 2, and 3. These homologous isoenzymes each con-
tain seven membrane-associated regions, and a central cy-
toplasmic domain possessing consensus sequences that are
substrates for phosphorylation by protein kinase C. Even
though they have 50–71% amino acid sequence identity,
they are located on three separate chromosomes, human
chromosomes 19, 8, and 16, respectively. This suggests gene
duplications with divergent evolution. They are diﬀerentially
regulated, each producing a diﬀerent size polymer [16, 17],
with independent gene regulation and kinetics.
A number of biologicals are directly able to regulate ex-
pression of HA synthase mRNA, including upregulation by
bFGF [18, 19], and several proinﬂammatory cytokines [20]
as well as suppression, by glucocorticoids [21, 22]. The latter
may account for the atrophic changes observed following
long-term glucocorticoid administration. Enhanced expres-
sion occurs also through lactoferrin, which also upregulates
transcription of a type-1 collagen gene, COL1A1 [23]. These
together suggest a mechanism by which wound healing is
stimulated.
The activity of the HAS proteins can also be modulated
by posttranslational modiﬁcations, such as ubiquitination
and dimerization [24]. Aberrant splice variants of HAS1
are able to modulate expression of the normally spliced
variant[25].AbnormalitiesoftheHAsynthaseenzymeshave
been associated with transformation and tumor metastases
[2, 26]. Inherited and acquired variations in the HAS1 gene
can contribute to disease progression in multiple myeloma
and in Waldenstrom’s macroglobulinemia [27]. Stimulation
of the HA synthases in cultured cells in the presence of
increased glucose promotes the deposition of an HA-rich
matrix[28,29].This matrixis highlyadhesiveformonocytes
and promises to provide new insights into diabetes. The
HAS genes and their gene products are obviously tightly
controlled at a vast number of levels, reﬂecting the extreme
importance of HA in so many biological systems and the
involvement in so many disease states [30].
4.HyaluronanCatabolism
The breakdown of HA in tissues can occur by two entirely
separate mechanisms, either enzymatically, by a class of
enzymes known as hyaluronidases, or by cleavages that are
nonenzymatic oxidation reactions.
4.1. The Hyaluronidases. Hyaluronan metabolism is extraor-
dinarily active in vertebrates. The average 70Kg individual
has approximately 15g of HA, 5g of which turns over daily.
HA has a half-life of 3–5 minutes in the circulation and
just days in most tissues [31, 32]. Why the body eliminates
HA so rapidly is not known. Hyaluronan is a scavenger of
free radicals and reactive oxygen species. Removing these
hazardous molecules and other toxic materials quickly may
explain the rapid rate of HA elimination. The function of
HA as a mechanism for the removal of toxins has not been
explored but deserves attention.
There are two separate mechanisms for removing HA
from the body, local cleavage reactions, catalyzed by free
radicals and enzymatic activity, and by whole body elim-
ination through the action of liver and kidneys. Ligation
of the hepatic or renal arteries causes an instant rise in
circulating HA levels [33], demonstrating the eﬃciency of
suchmechanisms. Clinically,thisexplains alsothehighlevels
of HA in patients in renal or hepatic failure, as well as in
patients following liver or kidney transplants experiencing
transplant rejection.
There are several classes of enzymes referred to as hya-
luronidases: (1) prokaryotic enzymes that are eliminases,
yielding disaccharides as the predominant products, (2) the
eukaryotic enzymes that use a hydrolytic cleave reaction,
adding water across the bond to be cleaved. Both of these
classes of endoglycosidases are enzymes that cleave β-endo-
N-acetylglucosamine bonds. The prokaryotic enzymes have
speciﬁcity for HA, while the eukaryotic enzymes are also
able to cleave chondroitin sulfate, albeit at a much slower
rate, and (3) a curious class of hyaluronidases that are
β-endoglucuronidases used by leeches and other inverte-
brates. Much less is known about this class of enzyme.
Eukaryotic hyaluronidases were until recently relatively
neglected enzymes, largely because of the diﬃcult in puri-
fying them. Hyaluronidases are extremely unstable in the
absence of detergents and protease inhibitors. They occur
in very low concentrations, with activities one log greater
than other globular enzyme proteins. The concentration of
hyaluronidase in human plasma is 60ng/mL [34].
There are six hyaluronidase-like sequences in the human
genome, while rodents have seven such sequences. All are
transcriptionally active with unique tissue distributions. In
the human, three genes (HYAL1, HYAL2,a n dHYAL3)a r e
found tightly clustered on chromosome 3p21.3. Another
three genes (HYAL4, PHYAL1 (a pseudogene), and PH20,
sperm adhesion molecule1 (SPAM1)) are clustered similarly
on chromosome 7q31.3 [35].
The enzymes HYAL1 and 2 constitute the major hyalu-
ronidases in somatic tissues; HYAL1, an acid-active lyso-
somal enzyme, was the ﬁrst somatic hyaluronidase to be
isolated and characterized. Why an acid-active hyaluronidase
should occur in plasma is not clear. HYAL1 is able to utilize
HA of any size as a substrate and generates predominantly
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plasma membranes by a GPI (glycosylphosphatidylinositol)
link.
The schema for HA catabolism [36, 37] indicates that
HMW HA is taken up by cells by the concerted eﬀort of the
receptor CD44, the enzyme HYAL2, and the proton pump
Na+H+ exchanger-1(NHE1).Anacidicmicroenvironmentis
created on the surface of the cell in membrane invaginations
termed “lipid rafts” [38]. HYAL2 cleaves the HMW HA
to a limit product of approximately 20kDa, or about 50
disaccharide units. The resulting HA fragment is delivered
to early endosomes and to lysosomes wherein the lysosomal
enzyme HYAL1 cleaves the HA further to predominantly tet-
rasaccharide fragments. HYAL1, in the artiﬁcial test tube
environment,canacceptanysizedHApolymerasasubstrate
and degrade it to the limit tetrasaccharide. The additional
activities of the lysosomal exoglycosidases, β-glucuronidase,
and β-hexosaminidase cleave fragments to single hexose
sugars that then exit lysosomes to enter cytosolic pathways.
NotalltissuesthatcontainHYAL1activitysynthesizethat
enzyme. Active endocytosis of the protein from the circula-
tion occurs [39]. Monocytes contain no mRNA for HYAL1,
yet have very high levels of enzyme activity (unpublished
observations). Megakaryocytes and platelets contain no
HYAL1 [40], perhaps because they lack the receptors for
endocytosis of circulating HYAL1.
Evidence from an unexpected quarter sheds light on this
anomaloussituation.Inthelysosomalstoragediseasetermed
X-disease,themannitol-6-Preceptorsforlysosomalenzymes
are defective. In such cultured ﬁbroblasts, most lysosomal
enzymes are absent, but levels of HYAL1 are normal. This
suggests that the HYAL1 is taken by an unknown and, as yet
unidentiﬁed receptor, one that is not aﬀected by the lesion
in the mannose-6-P receptor pathway. From this, it can be
deduced that the unknown receptor is absent or blocked in
platelets and megakaryocytes.
These hyaluronidases are endoglycolytic activities with
speciﬁcity for the β1-4 glycosidic bond. These enzymes have
ahydrolyticmechanismofaction,comparedtotheeliminase
mechanism of prokaryotes. Isolation and characterization
of the vertebrate enzymes indicate that they are ubiquitous.
Rapid progress in genome analyseshas provided much infor-
mation. There are six hyaluronidases in the human genome
[41,42]withsevenbeingpresentinthemurinegenome.Two
hyaluronidases, HYAL1 and HYAL2, are the predominant
activities in somatic tissues, working in concert to degrade
HMW polymers to tetrasaccharides as the predominant end
product.
HYAL1isanacid-activelysosomalenzymeandtheﬁrstto
be isolated and characterized [34, 43, 44]. HYAL1 is a 57kDa
polypeptide that also occurs in a processed 45kDa form, the
resultoftwoendoproteasereactions,disulﬁdebondsbinding
the resulting two chains together. These two forms do not
have a zymogen-active enzyme relationship, since they have
similar speciﬁc activities. The fragment generated by the
cleavage reactions may also have an important function in
the overall economy of the niche.
An inactive 70-kDa-precursor form of HYAL1 is present
in some mammalian sera, including calf serum, as can be
observed on electrophoretic gels by Western blot. The
inactive unprocessed form occurs in sera from many species
in which it is claimed that no acid-active enzyme exists [45].
It is not clear why an acid-active enzyme is present in
the circulation. Some animals have no apparent activity in
serum or plasma. At one time, it was assumed that the serum
enzyme, now known to be HYAL1, could not be an impor-
tant activity if it was entirely absent in some mammalian
species. However, it has been demonstrated that an inactive
highmolecularformoccurs,asshownbyWesternblotingels
of such sera (R. Stern, unpublished observations).
HYAL2 has several forms, one being anchored to the
external surface of plasma membranes by a GPI-link. HYAL2
also occurs in a processed soluble form, and a portion can be
detected in early lysosomes. The several forms are thought to
shuttlebetweenvariouscellularcompartmentsintheprocess
of HA internalization and degradation, as it is delivered from
the extracellular space in steps to the ﬁnal destination in
acid lysosomes. HYAL2 cleaves the large HA polymer to a
limitproductof20kDa,orabout50disaccharideunits,while
HYAL-1 in vitro is able to digest any HA chain including
the high-molecular-weight polymer to the tetrasaccharide
fragment.
While only two hyaluronidases participate in HA catab-
olism innormalsomatictissues,aberrantexpression ofother
hyaluronidases can be detected in cancerous tissues. One of
the products of the six hyaluronidase-like sequences in the
human genome, PH-20, a neutral-active hyaluronidase, was
originallyassumedtobespermspeciﬁc.Usingmoresensitive
techniques, the enzyme can be detected in other tissues, in
the epididymis, seminal vesicles, and prostate gland [46].
Additionally, PH20 can be aberrantly expressed in a number
of human malignancies [47–50].
4.2. Nonenzymatic Cleavage. A portion of the breakdown
of HA takes place by oxidation reactions. The cleavage is
caused by unstable molecules, by reactive oxygen species
(ROS) and by free radicals [51, 52]. The proportions of HA
catabolism between enzymatic and oxidative cleavage reac-
tions have not been established, though it is assumed that
the former predominates. These proportions may vary con-
siderably, depending on the physiological situation. Early in
acute inﬂammation, the myeloperoxidase enzyme reaction
associated with neutrophils may be an important catalytic
mechanism for HA breakdown.
There are major diﬀerences between the products of en-
zymatic and free radical catabolism. While enzymatic cleav-
age results in polymers that are identical in structure to the
parent polymer, oxidative cleave generates polymers with
oxidized termini. Such structural diﬀerences may provide
metabolic cues. It is possible to determine the proportion
of HA breakdown enzymatic and nonenzymatic mecha-
nisms, based on such diﬀerences between their respective
reaction products. However, to date, there has been no
research performed to address this issue, despite its intrinsic
importance in biology. ROS are constantly being produced
in the body and are tightly regulated to maintain a redox
balance or homeostasis, together with a series of antiox-
idants and attendant reactions, for example, glutathione,
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HA, hyaluronidases, and these redox mechanisms constitute
interactions between a number of physiological situations as
well as the pathophysiology of infection, inﬂammation, and
the immune responses. This is an important area of biology
also that has been relatively neglected, although inroads are
currently being undertaken [53].
5.HyaluronanReceptors
There are an ever-growing number of HA receptors. A co-
nundrum to be dealt with is the indistinct boundary
between membrane-bound receptors and HA-binding pro-
teins, known as hyaladherens. The prominent receptor,
CD44, also occurs as a soluble circulating protein, perhaps
functioning as a decoy for the cell-bound receptor.
5.1. CD44. T h eC D( c l u s t e r so fd i ﬀerentiation) system is
commonly used as cell markers in immunophenotyping.
CD44isconsideredthemostprominentreceptorforHA.Itis
a transmembrane glycoprotein that occurs in a wide variety
of isoforms, products of a single gene with expression of 10
variant exons [54]. The CD44 isoform can occur with the
total absence of variant exon insertions, referred to as CD44S
or the standard form. The variant exons are all inserted in
variouscombinationsintoasingleextracellularpositionnear
the membrane insertion site. Additional variations in CD44
structure occur as a result of posttranslational glycosylation,
addition of various GAGs, including chondroitin sulfate and
heparan sulfate. CD44 is widely distributed, being found on
virtually all cells except red blood cells.
CD44 plays a major role in myriads of physiological pro-
cesses [55, 56] and is particularly important in malignancy,
intumorcellhomingandmetastasis.Thereisavastliterature
on the combinations of variant exons that occur on tissue-
speciﬁc cancers.
5.2. RHAMM. RHAMM is also given the designation
CD168. This protein exists in the nucleus and cytoplasm, as
well as on the cell surface. This receptor binds to the mitotic
spindle, participates in cell locomotion, focal adhesion, and
contact inhibition. It also has many functions that support
the transformed state [57], levels being over-expressed in
many human cancers. To designate it as a receptor only is
obviously a simpliﬁcation. Many of the proteins associated
with HA metabolism have multiple functions. The names
scientists apply to these proteins can be misleading, as the
assumption is often made that their names designate their
only function.
RHAMM can partner with CD44 on cell surfaces where
it enhances CD44-mediated signaling. It thus contributes to
tumor progression by enhancing tumor-promoting proper-
ties of CD44. The close coordination of the RHAMM and
CD44 receptors is further supported by the observation that
mice with a genetic deletion of CD44 upregulate expression
of RHAMM, the latter being able to substitute for many of
the functions usually carried out by CD44 [58].
5.3. HARE. HARE (HA receptor for endocytosis), also
known as stabilin-2, binds and internalizes not only HA
and chondroitin, but also sulfated GAGs such as chondroitin
sulfate, dermatan sulfate, and heparin [59].
5.4. LYVE-1. LYVE-1 stands for (lymphatic vessel endothe-
lial HA receptor)-1. This cell surface receptor on lymphatic
endothelial cells for HA is the subject of debate, but its
conservation in evolution indicates that it is an important
molecule [60]. LYVE-1 is not restricted to lymphatic vessels,
but is also expressed in liver sinusoids, suggesting that it is
involved in HA drainage in lymphatics and liver, and there-
fore in overall body turnover.
An unexpected complexity is the regulation of LYVE-
1 HA-binding activity by glycosylation and sialylation.
This receptor, like CD44, may become active only after
appropriate unmasking in vivo [61].
5.5. TLR-2 and -4. TLR (toll-like receptors) -2, and -4,
CDs 282 and 284 respectively, are membrane receptors re-
sponsible for initiating action from cells of the innate im-
mune system by stimulation of pathogen-associated molec-
ular patterns (PAMPs) [62, 63]. TLR-2 is present on ma-
crophageswhere,whenstimulatedbygram-positivebacteria,
it induces transcription factor NF-KappaB and thereby
the release of proinﬂammatory cytokines. TLR-4 is also
found on macrophages where the stimulation is induced by
lipopolysaccharide on gram-negative bacteria. These in turn
initiate signal transduction pathways within macrophages.
Since the cellular coat of both Streptococcus A and C contain
HA components, data suggests that short chain HA may
function as a PAMP in the inﬂammatory environment. This
signal transduction has been demonstrated in lung and
epithelial tissue in both infectious and traumatic situations
[60–64].
6. Chain Length as an Information-Rich System
Despite its simple repeating structure, HA has a wide range
and occasionally contradictory functions, even though it is
without branch points and without sulfation or other
secondary modiﬁcations. The multiple functions can be at-
tributed to diﬀerences in chain length. The variation in size
is an extraordinarily rich informational system [65, 66].
In general, high-molecular-weight HA occurs in normal
healthy tissues. Fragmented HA, on the other hand, is
highly inﬂammatory, angiogenic, and immune stimulatory,
a reﬂection of tissues under stress. The large HA polymers
are, in marked contrast, anti-inﬂammatory, anti-angiogenic,
and immunesuppressive.
Hyaluronan is critical in edema, inﬂammation, and
during wound healing. Polymer size is critical throughout
these processes. Tissue edema is one of the ﬁve cardinal signs
of inﬂammation. Such swelling is comprised predominantly
of HA, a concept that is not suﬃciently appreciated. Indeed,
many of the inﬂammatory cytokines induce HA production,
and, conversely, HA fragments induce such cytokine synthe-
sis in a self-stimulatory cycle [55, 67]. Hyaluronan, in a size-
speciﬁc manner, also modulates a great number of immune
responses [68].6 Biochemistry Research International
7.The MalignantConnection
Hyaluronan playsa critical rolein malignancy [69–71],levels
of HA often correlating with tumor aggressiveness and poor
prognosis. Such correlations have been validated for both
epithelial tumors (carcinomas), as well as for malignancies
of mesenchymal origin (sarcomas). Of particular interest is
the observation that the HA content of the nonmalignant
stromal component of tumors also correlates with malignant
aggressiveness, suggesting that the stromal component is not
entirely normal. Tumors may commandeer stromal pop-
ulations from bone marrow or induce expansion of stem
cell-like or populations of ﬁbroblasts that resemble embry-
onic ﬁbroblasts.
The balance of synthesis and degradation of HA is reg-
ulatory for cancer cell proliferation and motility in vitro,
and in tumor invasion and progression in vivo [72–76].
Of particular importance is the essential role of HA in the
microenvironment during the process of tumor initiation
and early progression [76]. As mentioned, the importance
of local stroma in supporting such events, and peculiarities
of the attendant HA metabolism is critical for success of the
cancer. A recent volume proﬁles the many functions of HA
in cancer biology and in the transformed state [77].
8.HyaluronaninSkin
More than 50% of total body HA is contained in skin and
thus requires “special handling.” It is responsible for skin
hydration, and protects skin against free radical damage,
particularly against UV light, both UVA and UVB.
There are many reports that document decreasing levels
of skin HA with aging, with the suggestion that this is
responsible for the deteriorating appearance of skin with
aging. Such observations are based on histochemical staining
criteria. However, biochemical extraction indicates that HA
levels remain constant with age. The HA becomes increas-
ingly tissue associated, becoming progressively more resis-
tant to extraction as a function of age [78].
The apparent results of the histochemical investigations
can be explained by increasing competition between tissue
proteins for HA binding sites and the HA-binding peptide
as a function of age. The HA, encased within tissue proteins
may be restricted from functioning as a hydrating molecule.
This proviso also indicates that the HA-staining procedure,
as normally performed with an HA-binding peptide, is not a
quantitative procedure.
Hyaluronaninskinoccursinbothdermisandepidermis,
with dermis containing the greater proportion. Epidermal
HA is more loosely associated and more easily extracted
from tissue. Formalin, an aqueous ﬁxative, easily removes
most HA from epidermis and is less able to extract HA from
dermis. Alcoholic acid formalin enhances histolocalization
of epidermal HA, and indicates that considerable levels are
contained therein [79].
Skin HA has a very rapid turnover, with a half-life of 1-2
days in the epidermis [80]. The turnover rate in the dermis is
similar, with catabolism occurring in liver and lymph nodes,
following lymphatic drainage [31]. The turnover mechanism
intheepidermisisnotclearandmaybeacombinationoffree
radical fragmentation stimulated by UV light, and enzymatic
degradation.
Hyaluronan is most prominent in the upper spinous
and granular, where much of it is extracellular. In the basal
layer, HA is predominantly intracellular and is not easily
eluted out during aqueous ﬁxation. Basal keratinocyte HA
is involved in mitotic events, presumably, while extracellular
HA in the upper layers of the epidermis is involved in barrier
disassociation and sloughing of cells.
Hyaluronan of the epidermal ECM forms two diﬀerent
structures; a pericellular coat close to the plasma membrane,
forming the pericellular matrix, and HA chains that coalesce
into large cables. Such cables, with induced expression
under inﬂammatory events, bind leukocytes, whereas the pe-
ricellular HA does not [28, 81].
The HA content of the dermis is far greater than that
of the epidermis. The papillary dermis has more prominent
levels of HA than the reticular dermis. Exogenous HA is
cleared from the dermis and rapidly degraded [31]. The
dermal ﬁbroblast provides the synthetic machinery for
dermal HA. What makes the papillary dermal ﬁbroblast
diﬀerent from other ﬁbroblasts is not known. However, these
cells have an HA synthetic capacity similar to that of the
ﬁbroblasts that line joint synovium, responsible for the HA-
rich synovial ﬂuid, or the hyalocytes of the eye that provide
the vitreous of the ocular chambers.
9. Recent Additions to the Many
Functions of HA
Despite the fact that HA does not give up its secrets
easily, new functions for HA continue to emerge. An in-
teresting connection has been described between HA and
autophagy. Hyperglycemia is one of many factors that
induces autophagy. Cells cultured in hyperglycemic medium
initiate a stress response that includes HA synthesis. The HA
is extruded into the ECM in a structural form recognized
by inﬂammatory cells [29]. Cyclin D3 is central to such
events. Abnormal deposits of HA and cyclin D3 occur in
diabetic rat glomeruli, indicating that a similar process
occursinvivo[82].Moreimportantly,theHAstressresponse
and autophagy may be major contributors to the multiple
pathologies associated with diabetes [28].
Matrix HA also has a dramatic eﬀect in immune reg-
ulation, on the phenotype of regulatory T cells [83]. The
HA-containing ECM functions as a biosensor for the in-
ﬂammatory microenvironment important for immune tol-
erance. HA that is HMW promotes induction of IL-10-
producing regulatory T cells from T-cell precursors, while
fragmented HA does not. This has been demonstrated in an
IL-10-dependent mouse colitis system, in which HMW HA
suppresses disease through such T-cell induction. The ability
ofHMWHAtocross-linkCD44onthecellsurfacemaybean
underlying mechanism for this phenomenon [84], thereby
maintaining immunological tolerance.Biochemistry Research International 7
10. Conclusion
There remain many questions regarding this highly ionic as
well as highly ironic polymer. How do cell response mech-
anisms distinguish between the diﬀerent sizes of linear HA
polymers, given the identity of their chemical structures?
One intuitive answer is that various HA chain sizes take
on diﬀerent physical-chemical conﬁgurations and that the
sensing mechanisms respond to such diﬀerences. Another
possibility is that diﬀerent-sized HA fragments can associate
withdiﬀerentproﬁlesofhyaladherensorthattherearemajor
changes in aﬃnity, depending on HA size. It is probably a
combinationofallsuchfactorsthatdeterminethediﬀerences
in responses.
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